Mabpharm Ltd. engages in the research, development, and manufacture of monoclonal antibody drugs for the treatment of cancer and autoimmune diseases. The company is headquartered in Taizhou, Jiangsu and currently employs 383 full-time employees. The company went IPO on 2019-05-31. The Company’s main products include CMAB009 Enlituo (cetuximab β injection), CMAB007 Aomaishu (Omalizumab α for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Company’s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The firm is also engaged in the transfer of intellectual property. The firm mainly conducts its business in the domestic market.
02181.HK stock price ended at $0.51 on 목요일, after rising 0.00%
On the latest trading day Feb 12, 2026, the stock price of 02181.HK rose by 0.00%, climbing from $0.51 to $0.51. Throughout the session, the stock experienced a volatility of 0.00%, with prices fluctuating between a daily low of $0.51 and a high of $0.51. Alongside this price increase, trading volume also rose by 18.0K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, -- shares were traded, amounting to a market value of approximately $2.1B.
02181.HK 기술적 시그널
기술적 시그널 요약
구매 신호 2
중립 신호 1
매도 신호 4
Strong Sell
Sell
Neutral
Buy
Strong Buy
02181.HK은 현재 2개의 매수 신호와 4개의 매도 신호를 보이고 있습니다. 이 주식은 12:00 AM 이후로 상승 추세 상태에 있으며, 이 기간 동안 총 가격 변동률은 --입니다. 전반적으로 기술적 지표들은 중기적으로 Sell 전망을 나타내고 있습니다.
02181.HK에 대한 강세/약세 신호
이동평균, RSI, MACD, 거래량 등 핵심 지표를 분석하여 02181.HK 의 강세/약세 시그널을 생성합니다. 이 인사이트를 활용해 더 현명한 투자 결정을 내리세요.